Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.52%
+3.51%
+210.53%
+1.67%
AMGN
Amgen
$295.54
Login to see Amgen (AMGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Trading below its fair value
Investors confidence is positive
Chart
$282.73 (+4.53%)
$299.02 (-1.16%)
$272.41 (+8.49%)
$319.66 (-7.55%)
AMGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
AMGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
AMGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AMGN Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayAMGN Earnings
The TTM reflects 12-month period, providing review of AMGN financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
MRNA
27.32
-0.73%
BIIB
152.21
-1.19%
EXEL
39.38
-0.95%
CRSP
70.62
+0.61%
CHRS
1.71
+0.59%
What is AMGN current stock price?
What are AMGN stock strengths?
What risks are associated with AMGN stock?
When is AMGN next earnings report?
What is AMGN market cap and volume?
What is AMGN's current Stock IQ?
Should I buy AMGN stock right now?
Is AMGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for AMGN?
What does a 'Strong Sell' rating mean for AMGN?
What factors influence AMGN's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.52%
+3.51%
+210.53%
+1.67%
AMGN
Amgen
Current Price
$295.54
Stock Insights
Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Trading below its fair value
Investors confidence is positive
Linked to AMGN
MRNA
27.32
-0.73%
BIIB
152.21
-1.19%
EXEL
39.38
-0.95%
CRSP
70.62
+0.61%
CHRS
1.71
+0.59%
Login to unlock Amgen (AMGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$282.73 (+4.53%)
$299.02 (-1.16%)
$272.41 (+8.49%)
$319.66 (-7.55%)
AMGN Analysts Opinion
AMGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
AMGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AMGN Street view is extremely bullish and have positive views on the near-term outlook
AMGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayAMGN Earnings
The TTM data reflects the most recent 12-month period, providing overview of AMGN financial performance.
AMGN Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
AMGN Latest Analysis
Amgen Unveils New DTC Program Cuts Cholesterol Drug Price by 60%. AMGN rolls out AmgenNow a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
Today
Amgen (AMGN) Stock Sinks As Market Gains: Heres Why. Amgen (AMGN) reached $294.12 at the closing of the latest trading day reflecting a -1.27% change compared to its last close.
Mon Oct 6, 2025
Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administrations Call To Lower Drug Prices. ) on Monday launched .AMGN stock is trending lower. This follows results demonstrating Repathasignificantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the .In support of the Trump Administration’.s efforts to lower drug prices for Americans Repatha will be available through AmgenNow at a monthly price of $
Mon Oct 6, 2025
Heres Why Amgen (AMGN) is a Strong Value Stock. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.
Mon Oct 6, 2025
Amgen to sell cholesterol drug at 60% discount to cash-paying US patients.
Mon Oct 6, 2025
Amgen Launches AmgenNow Direct-to-patient Program. Available To Repatha Patients . (RTTNews) - Amgen (AMGN) announced the launch of AmgenNow a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a monthly price of $239 nearly 60% lower than the current United States list price. The program is open to all pat
Mon Oct 6, 2025
Amgen to sell cholesterol drug at 60% discount direct to US consumers.
Mon Oct 6, 2025
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Thu Oct 2, 2025
Amgens Phase 3 VESALIUS-CV Study Of Repatha Meets Primary Endpoints . (RTTNews) - Amgen Inc. (AMGN) on Thursday announced positive results form the Phase 3 VESALIUS-CV study of Repatha in adults with high cardiovascular risk without prior heart attack or stroke.
Thu Oct 2, 2025
2 High-Yield Dividend Growth Stocks to Buy in October and Hold for a Decade or Longer. Key PointsWatsco and Amgen both offer dividends that are more than double the benchmark average.
Thu Oct 2, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
AMGN Stock trends
AMGN Stock performance
AMGN Stock analysis
AMGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings